Redmile Group, LLC Iveric Bio, Inc. Transaction History

Redmile Group, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$18.67 - $24.56 $5.54 Million - $7.29 Million	-296,905 Reduced 6.59%	4,205,206 $102 Million
Q4 2022 Feb 14, 2023	BUY	$17.24 - $23.95 $19 Million - $26.4 Million	1,102,211 Added 32.42%	4,502,111 $96.4 Million
Q3 2022 Nov 14, 2022	BUY	$9.4 - $18.59 $17.7 Million - $35 Million	1,881,000 Added 123.84%	3,399,900 $61 Million
Q2 2022 Aug 15, 2022	BUY	$9.12 - $18.9 $301,872 - $625,590	33,100 Added 2.23%	1,518,900 $14.6 Million
Q1 2022 May 16, 2022	SELL	$12.15 - $16.83 $172,530 - $238,985	-14,200 Reduced 0.95%	1,485,800 $25 Million
Q4 2021 Feb 14, 2022	BUY	$13.83 - $18.78 $20.7 Million - $28.2 Million	1,500,000 New	1,500,000 $25.1 Million

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Redmile Group, LLC with notifications on news.